People · Operator
Named in public records as an officer, director or promoter · active 2020–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| GeneCentric Therapeutics, Inc. | — | Biotechnology | Series A | $21.6M | $6.7M | 2020 |
CHARLES PEROU at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside CHARLES PEROU on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Clay Thorp | 1 | 10 |
| Arnold Levine | 1 | 4 |
| Michael Milburn | 1 | 3 |
| Ellen Lubman | 1 | 2 |
| Myla Lai-Goldman | 1 | 2 |
| Don Hardison | 1 | 2 |
| Arnold Neil Levine | 1 | 1 |
| Charles Neil Perou | 1 | 1 |
| David Neil Hayes | 1 | 1 |
| Prasanth Reddy | 1 | 1 |
| Arnold V. Levine | 1 | 1 |
| Ellen V. Lubman | 1 | 1 |
| Michael V. Milburn | 1 | 1 |
| Perou V. Charles | 1 | 1 |
| Clay V. Thorp | 1 | 1 |
| Myla V. Lai-Goldman | 1 | 1 |
| Clay Neil Thorp | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.